Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARK Genomic Revolution ETF (NY:ARKG)

46.02 -2.23 (-4.63%)
Delayed Quote Updated: 2:39 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARK Genomic Revolution ETF

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock. ↗
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12. 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗
The gene-editing biotech stock is down more than 12% this year. 
Via The Motley Fool
Topics ETFs Lawsuit
News headline image
Cathie Wood's Ark Has Delivered Just a 13.8% Annualized Return Since 2014, Roughly Matching the S&P 500. Should You Trust Her Bold Predictions for 2030? ↗
Are her big ideas turning into big returns? 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗
Via Stocktwits
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet. ↗
Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market. 
Via The Motley Fool
Topics ETFs Government
News headline image
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating ↗
This particular position isn't rooted solely in the science you've heard most about from the biopharma company so far. 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Just Bet Big on This Biotech Stock ↗
Ionis Pharmaceuticals' shares are down more than 27% so far this year. What does Cathie Wood see that others are missing? 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Cathie Wood's biotech ETF has largely moved on from the vaccine maker. 
Via The Motley Fool
Topics ETFs
News headline image
Cathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy? ↗
Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Why Is CRSP Stock Falling Pre-Market Today? ↗
The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031. 
Via Stocktwits
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗
COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗
The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression. 
Via Stocktwits
News headline image
TWST Shares Rise 8% — What’s Driving The Rally? ↗
Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October. 
Via Stocktwits
Topics Artificial Intelligence ETFs
News headline image
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50% ↗
This company's first product has started to generate revenue. 
Via The Motley Fool
Topics ETFs
News headline image
Why Tempus AI Stock Soared This Week ↗
A well-known analyst believes this AI healthcare stock has room to soar. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? ↗
Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
Via Benzinga
Topics ETFs
News headline image
Wellgistics Health's 200% Surge Puts AI-Pharma Tie-Ups On The ETF Map ↗
Wellgistics Health (WGRX) soared 155% after a Datavault AI tie-up, stirring buzz around AI and healthcare ETFs. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Wellgistics And DataVault Team Up To Transform Prescription Tracking ↗
DataVault AI and Wellgistics Health are collaborating to bring blockchain technology to the US prescription drug market. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet ↗
Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure. 
Via Benzinga
Topics ETFs Government
News headline image
Nancy Pelosi, Cathie Wood Align On These 4 Stocks – Do You Own Any? ↗
Shared stocks between Nancy Pelosi and Cathie Wood include Alphabet, Amazon, NVIDIA, and Tempus AI. They also both own stakes in private company Databricks. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Nancy Pelosi's Tempus Play Might Be Smartest Trade In Washington — Stock Surges 200% ↗
An AI stock disclosed as a new 2025 purchase by Nancy Pelosi is up over 200% since she took the position in January. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI ↗
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. (NASDAQ:AMD) and Bullish Inc. (NYSE:BLSH), while selling shares o 
Via Benzinga
News headline image
Cathie Wood, Dan Ives Align On These 11 AI Stock Picks — Some Might Surprise You ↗
Cathie Wood and Dan Ives have 11 stocks in common across ETFs. A look at the AI stocks the two key figures are betting on. 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Cathie Wood's Ark Pivots: Sells Tempus AI After FDA Win, Loads Up On Amazon, Figma And This Trendy Crypto Stock ↗
Cathie Wood-led Ark Invest sold shares of Tempus AI, bought Bullish, Amazon, and Figma. The moves align with recent achievements and advancements of the companies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood's Ark Dumps $2.1 Million Of This Hot AI Stock Despite Recent Acquisition Boost ↗
On Tuesday, Cathie Wood-led Ark Invest sold shares of Tempus AI Inc (NASDAQ: TEM) through ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK) totaling $2.1 million. This follows Tempus AI's... 
Via Benzinga
Topics Artificial Intelligence ETFs
News headline image
Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers ↗
Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses. 
Via Benzinga
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.